Vince Parry

Vince Parry is the "chief branding officer" at InChord Communications. His "genius" has been to help pharmaceutical companies market drugs to healthy people by creating new condition categories or redifining aspects of conditions requiring medication.

Marketing Campaigns

Le Monde Diplomatique, May 2006 ^[1], reports:

Vince Parry is the cutting edge of that global marketing. An expert in advertising who works from his mid-town Manhattan office in New York, Parry specialises in the most sophisticated form of medicine salesmanship: he works with drug companies to help create new diseases.
In an astonishing publication, The Art of Branding a Condition, he recently revealed the ways in which companies are involved in fostering the creation of medical disorders (1). Sometimes a little-known condition gets fresh attention, sometimes an old disease is redefined and renamed, and sometimes a whole new dysfunction is created. Parry’s personal favourites include erectile dysfunction, adult attention deficit disorder, and pre-menstrual dysphoric disorder (which is so controversial a classification that some researchers say it doesn’t exist).
Branding disease
With rare candour Parry explains how pharmaceutical companies take the lead, not just in branding such blockbuster drugs as Prozac and Viagra, but in branding the very conditions that create the markets for those drugs. Under the leadership of the drug marketers, Madison Avenue experts such as Parry collude with medical experts to “create new ideas about illnesses and conditions”. The goal, Parry says, is to give drug company customers around the world “a new way to think about things”. The aim is to make a direct link between the condition and the company’s medicine, to maximise its sales.

Articles

• Vince Parry, The Art of Branding a Condition, Medical Marketing & Media, London, 2003.

External Resources

• ^Alan Cassels and Ray Moynihan, US: selling to the worried well:Pharmaceuticals for healthy people, Le monde diplomatique, May 2006. (LMD synopsis: US pharmaceutical companies have long known that the potential market for their products is limited by the finite number of sick people; so they have turned to the healthy for further expansion of their markets, using exploitative, fear-inducing advertising techniques.)